ACC 2023 Buzz Report
What does it take to make an impression? As we reflect back on ACC 2023, so many companies stand out as leaders in the cardiology space. Between sipping champagne and eating beignets, FloodGate Medical had the opportunity to dive deeper with many of the show’s standouts. The growth of the cardiovascular devices market size, expected to reach nearly 86B by 2028, is driven by the rise of chronic heart diseases. This provides the momentum towards higher adoption of technologically advanced cardiology devices for both diagnostic and surgical purposes.
There were a few main technology trends that stood out to us during the show: Artificial Intelligence (AI) and machine learning algorithms to improve monitoring for several heart conditions, better and more efficient diagnostic devices as well as software for improved disease prevention and management (with some companies establishing new gold standards of care), 3D patient solutions and continuous advancement of technologies used in minimally invasive procedures over open surgery. We’ve recapped our takeaways of who made the biggest splash at this year’s show in New Orleans in our Buzz Report below.
With 50 years in the industry and the #1 leading blood pressure monitors in the US under their belt, Omron recently transitioned from being solely a monitor at home device to software as a service (SaaS) with their VitalSight: a full remote patient monitoring (RPM) program focused on eliminating heart attacks and strokes. Their VP of Digital Health and Software spoke on how these therapeutic platforms are able to provide actionable data for both patients and clinicians that result in better overall health outcomes.
ReCor just released their third consistent sham-controlled clinical trials that had awesome patient outcomes and demonstrated their Paradise ultrasound renal denervation (uRDN) System can safely lower blood pressure and be used as an effective and adjunctive therapy for hypertension management.
Ziosoft addresses changing needs in advanced visualization and analysis by providing clinicians access to tools based on transformational technology, which removes the barriers of accessibility while maintaining performance and image integrity. TAVR allows comprehensive pre-procedure annulus assessment using static and dynamic measurement tools. Keep your eyes out for a new cardiac MR being released by Ziosoft this year.
A growing leader in cardiovascular diagnostic solutions who are improving the space by automating the process, minimizing the risk of contrast-induced acute kidney injury (CI-AKI) for coronary catheterizations, and saving overall contrast cost for hospitals. Their CVi is in over 50% of cath labs across the US already.
A company using the power of AI algorithms to provide surgeons with accurate, affordable and fast 3D visualizations and 3D printed models to improve surgical outcomes.
Leading with confidence and attacking with control, the AlphaVac system by Angiodynamics is an off the shelf, easy to assemble, emergent mechanical aspiration device, allowing for efficient procedure time & eliminating the need for perfusionist support. This is the largest bone mechanical aspiration device on the market.
There’s a new gold standard of care in heart disease being implemented by Cleerly. Their AI algorithms generate a 3D model of the patient’s coronary arteries, identify their lumen and vessel walls, locate and quantify stenoses, as well as identify, quantify and categorize plaque, even vulnerable plaque – able to catch disease very early and even prevent heart attacks. We have to admit – we’re pretty excited to see the future for this company and the improved technology for prevention – the future “mammogram” of cardiovascular disease prevention.
Wearable cardioverter defibrillator systems built by Kestra provide a modern approach with patient-focused design and advanced technology.
All eyes were on the newly developed Liposorber system indicated for adult & pediatric patients with nephrotic syndrome associated with FSGS.
Instead of “re-purposing” arterial devices, Inari Medical is pioneering venous-specific devices with venous anatomy and clot morphology in mind. Focusing on the critical vessels of venous disease, Inari has designed tools to treat both Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT). The FlowTriever and ClotTriever were designed as non-thrombolytic solutions to venous thromboembolism.
Cardiology medicine is one of the fastest and most evolving spaces in MedTech. The market should sustain strong growth with high demand for these devices and more. Most key players are anticipated to show robust involvement in research and development initiatives – which we also saw at the exhibit with many companies waiting on funding, just closed funding, or pending 510K or FDA approvals. What were your biggest takeaways from ACC 2023? We’d love to hear your thoughts on the show in the comments!